Zhuang Jing, Wang Xianding, Xu Liangzhi, Wu Taixiang, Kang Deying
Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, China.
Cochrane Database Syst Rev. 2013 May 31;2013(5):CD008575. doi: 10.1002/14651858.CD008575.pub2.
The prevalence of depression in women with polycystic ovary syndrome (PCOS) is high; one study has shown it to be four times that of women without PCOS. Therefore, systematic evaluation of the effectiveness and safety of antidepressants for women with PCOS is important.
To evaluate the effectiveness and safety of antidepressants in treating depression and other symptoms in women with PCOS.
We searched the following databases from inception to June 2012: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycINFO and Chinese National Knowledge Infrastructure, the metaRegister of Controlled Trials (controlled-trials.com), the National Institute of Health Clinical Trials register (clinicaltrials.gov) and the World Health Organization International Trials Registry Platform search portal (www.who.int/trialsearch/Default.aspx).
Only randomised controlled trials (RCTs) studying the effectiveness and safety of antidepressants for women with PCOS were included in this review.
The methodological quality of the trials was assessed independently by two review authors, in parallel with data extraction. The risk of bias in the included study was assessed in six domains: 1. sequence generation; 2. allocation concealment; 3. blinding of participants, personnel and outcome assessors; 4. completeness of outcome data; 5. selective outcome reporting; 6. other potential sources of bias.
We found no studies reporting any of our primary review outcomes (depression and allied mood disorder scores, quality of life and adverse events). Only one study with 16 women was eligible for inclusion. This study compared sibutramine versus fluoxetine in women with PCOS, and reported only endocrine and metabolic outcomes. It was unclear whether the participants had psychological problems at baseline. No significant difference was found between the groups for any of the measured outcomes.
AUTHORS' CONCLUSIONS: There is no evidence on the effectiveness and safety of antidepressants in treating depression and other symptoms in women with PCOS.
多囊卵巢综合征(PCOS)女性中抑郁症的患病率很高;一项研究表明,其患病率是无PCOS女性的四倍。因此,系统评估抗抑郁药对PCOS女性的有效性和安全性很重要。
评估抗抑郁药治疗PCOS女性抑郁症及其他症状的有效性和安全性。
我们检索了以下数据库,检索起始时间至2012年6月:Cochrane月经紊乱与生育力低下小组试验注册库、Cochrane对照试验中央注册库、MEDLINE、EMBASE、PsycINFO和中国知网、对照试验元注册库(controlled-trials.com)、美国国立卫生研究院临床试验注册库(clinicaltrials.gov)以及世界卫生组织国际临床试验注册平台搜索门户(www.who.int/trialsearch/Default.aspx)。
本综述仅纳入研究抗抑郁药对PCOS女性有效性和安全性的随机对照试验(RCT)。
两位综述作者在进行数据提取的同时,独立评估试验的方法学质量。纳入研究的偏倚风险在六个领域进行评估:1. 序列生成;2. 分配隐藏;3. 参与者、研究人员和结果评估者的盲法;4. 结果数据的完整性;5. 选择性结果报告;6. 其他潜在的偏倚来源。
我们未找到报告任何主要综述结果(抑郁及相关情绪障碍评分、生活质量和不良事件)的研究。仅有一项纳入16名女性的研究符合纳入标准。该研究比较了西布曲明与氟西汀对PCOS女性的影响,仅报告了内分泌和代谢结果。尚不清楚参与者在基线时是否存在心理问题。各测量结果在两组之间均未发现显著差异。
尚无证据表明抗抑郁药治疗PCOS女性抑郁症及其他症状的有效性和安全性。